ИНТЕРЛЕЙКИН 1 КАК МЕДИАТОР ВОСПАЛЕНИЯ И ТЕРАПЕВТИЧЕСКАЯ МИШЕНЬ
https://doi.org/10.14412/1995-4484-2011-1463
Аннотация
Интерлейкин 1 (ИЛ 1) впервые был описан в 40-х го- дах XX в. как вызывающий лихорадку фактор, высвобож- даемый активированными лейкоцитами. В то время он на- зывался «пирексин» или «эндогенный пироген» [1]. Как правило, клетки организма не способны к спонтанному синтезу ИЛ 1, а отвечают его продукцией на инфекцию, действие микробных токсинов, воспалительных агентов, других цитокинов, активированных компонентов компле- мента или системы свертывания крови [2, 3].
Список литературы
1. <div><p>Atkins E. Pathogenesis of fever. Physiol Rev 1960;40:580-646</p><p>Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010;6:232-41.</p><p>Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009;27:519-50. 4. Webb A.C., Collins K.L., Auron P.E. et al. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res 1986;5:77-85</p><p>Bensi G., Raugei G., Palla E. et al. Human interleukin-1 beta gene. Gene 1987;52:95-101.</p><p>Priestle J.P., Schar H.P., Gru tter M.G. Crystallographic refinement of interleukin 1 beta at 2.0 A resolution. Proc Natl Acad Sci USA 1989;86:9667-71.</p><p>Graves B.J., Hatada M.H., Hendrickson W.A. et al. Structure of interleukin 1 alpha at 2.7-A resolution. Biochemistry 1990;29:2679-84.</p><p>Dinarello C.A. The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314-25</p><p>Stevenson F.T., Bursten S.L., Fanton C., et al. The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece. Proc Natl Acad Sci USA 1993;90:7245-9.</p><p>Carruth L.M., Demczuk S., Mizel S.B. Involvement of a calpain-like protease in the processing of the murine interleukin 1α precursor. J Biol Chem 1991;266:12162-7.</p><p>Mosley B., Urdal D.L., Prickett K.S. et al. The interleukin-1 receptor binds the human interleukin-1α precursor but not the interleukin-1β precursor. J Biol Chem 1987;262:2941-4.</p><p>Black R.A., Kronheim S.R., Cantrell M. et al. Generation of biologically active interleukin1β by proteolytic cleavage of the inactive precursor. J Biol Chem 1988;263:9437-42.</p><p>Thornberry N.A., Bull H.G., Calaycay J.R. et al. A novel heterodimeric cysteine protease is required for interleukin1β processing in monocytes. Nature 1992;356:768-74</p><p>Franchi L., Eigenbrod T., Muсoz-Planillo R., Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10:241-7.</p><p>Lamkanfi M., Dixit V.M. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev 2009;227:95-105.</p><p>Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65.</p><p>Allen I.C., Scull M.A., Moore C.B. et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009;30:556-65</p><p>Thomas P. G., Dash P., Aldridge J.R. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase1. Immunity 2009;30:566-75.</p><p>Ghiringhelli F., Apetoh L., Tesniere A. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1βdependent adaptive immunity against tumors. Nat Med 2009;15:1170-8.</p><p>Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20-38</p><p>Netea M. G., Nold-Petry C.A., Nold M.F. et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 2009 113:2324-35.</p><p>Keller M., Ruegg A., Werner S., Beer H.D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008;132:818-31.</p><p>Fantuzzi G., Dinarello C.A. Interleukin-18 and interleukin-1β: two cytokine substrates for Ice (caspase-1). J Clin Immunol 1999;19:1-11.</p><p>Greten F. R., Arkan M.C., Bollrath J. et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 2007;130:918-31.</p><p>Guma M., Ronacher L., Liu-Bryan R. et al. Caspase 1-independent activation of interleukin-1beta in neutrophilpredominant inflammation. Arthr Rheum 2009;60:3642-50</p><p>Joosten L. A., Netea M.G., Fantuzzi G. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β. Arthr Rheum 2009;60:3651-62.</p><p>Guarda G., Dostert C., Staehli F. et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009;460:269-73.</p><p>Sims J.E., March C.J., Cosman D. et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988;241:585-9.</p><p>Dunne A., O'Neill L.A. The interleukin1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003:re3</p><p>Boraschi D., Tagliabue A. The interleukin1 receptor family. Vitam Horm 2006;74:229-54</p><p>Miller L.S., O'Connell R.M., Gutierrez M.A. et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006;24:79-91.</p><p>Jacques C., Gosset M., Berenbaum F., Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006;74:371-403.</p><p>Dinarello C.A. Biologic basis for interleukin1 in disease. Blood 1996;87:2095-147.</p><p>Chung Y., Chang S.H., Martinez G.J. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009;30:576-87</p><p>Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9.</p><p>Arend W.P., Joslin F.G., Massoni R.J. Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 1985;134:3868-75</p><p>Balavoine J.F., de Rochemonteix B., Williamson K. et al. Prostaglandin e2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 1986;78:1120-4.</p><p>Gabay C., Palmer G. Mutations in the IL-1RN locus lead to autoinflammation. Nat Rev Rheumatol 2009;9:480-2</p><p>Sims J.E., Giri J.G., Dower S.K. The two interleukin-1 receptors play different roles in IL-1 actions. Clin Immunol Immunopathol 1994;72:9-14.</p><p>Colotta F., Dower S.K., Sims J.E., Mantovani A. The type II decoy receptor: a novel regulatory pathway for interleukin 1. Immunol Today 1994;15:562-6</p><p>Smith D.E., Lipsky B.P., Russell C. et al. A central nervous system restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin1. Immunity 2009;30:817-31.</p><p>Garlanda C., Anders H.J., Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009;30:439-46.</p><p>Finckh A., Gabay C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr Opin Rheumatol 2008;20:269-75.</p><p>Bresnihan B., Alvaro-Gracia J.M., Cobby M. et al. Treatment of rheumatoid arthritis with recombinant human interleukin1 receptor antagonist. Arthr Rheum 1998;41:2196-204</p><p>Cohen S., Hurd E., Cush J. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebocontrolled trial. Arthr Rheum 2002;46:614-24</p><p>Jiang Y., Genant H.K., Watt I. et al. A multicenter, double-blind, doseranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthr Rheum 2000;43:1001-9.</p><p>Genovese M.C., Cohen S., Moreland L. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthr Rheum 2004;50:1412-9.</p><p>Cardiel M.H., Tak P.P., Bensen W. et al. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthr Res Ther 2010;12:R192</p><p>Drevlow B.E., Lovis R., Haag M.A. et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthr Rheum 1996;39:257-65.</p><p>Mertens M., Singh J.A. Anakinra for rheumatoid arthritis. Cochrane Database Syst. Rev 2009;21:CD005121.</p><p>Singh J.A., Christensen R., Wells G.A. et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96.</p><p>Nam J.L, Winthrop K.L., van Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.</p><p>Clark W., Jobanputra P., Barton P., Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: A systematic review and economic analysis. Health Technol Assess 2004;8:1-105.</p><p>Taylor P.C. Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des 2003;9:1095-106.</p><p>Donahue K.E., Gartlehner G., Jonas D.E. et al. Systematic Review: Comparative Effectiveness and Harms of DiseaseModifying Medications for Rheumatoid Arthritis. Ann Intern Med 2008;148:124-34.</p><p>Burger D., Dayer J.M., Palmer G., Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis- Best Pract Res Clin Rheumatol 2006;20:879-96.</p><p>Leslie K.S., Lachmann H.J., Bruning E. et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7.</p><p>Maksimovic L., Stirnemann J., Caux F. et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology 2008;47:309-10.</p><p>O'Connell S.M., O'Regan G.M., Bolger T. et al. Response to IL-1 receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 2007;24:85-9.</p><p>Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1 receptor antagonist in the Muckle-Wells syndrome. NEJM 2003;348:2583-4.</p><p>Goldbach-Mansky R., Dailey N.J., Canna S.W. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. NEJM 2006;355:581-92.</p><p>Hawkins P.N., Bybee A., Aganna E., McDermott M.F. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthr Rheum 2004;50:2708-9</p><p>Hawkins P.N., Lachmann H.J., Aganna E., McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthr Rheum 2004;50(2):607-12.</p><p>Mirault T., Launay D., Cuisset L. et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthr Rheum 2006;54:1697-700.</p><p>Rynne M., Maclean C., Bybee A. et al. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 2006;65:533-4.</p><p>Ross J.B., Finlayson L.A., Klotz P.J. et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cut Med Surg 2008;12:8-16.</p><p>Hoffman H.M., Yasothan U., Kirkpatrick P. Fresh from the pipeline: Rilonacept. Nat Rev Drug Discov 2008;7:385-6.</p><p>Kapur S., Bonk M.E. Rilonacept (Arcalyst), an Interleukin-1 Trap for the Treatment of Cryopyrin-Associated Periodic Syndromes. P-T 2009;34:138-41.</p><p>Toker O., Hashkes P.J. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biol Targ Ther 2010;4:131-8.</p><p>Church L.D., McDermott M.F. Canakinumab, a fully-human mAb against IL-1β for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-9.</p><p>Novartis: Ilaris prescribing information: http://www.pharma.us.novartis. com/productpi/pdf/ilaris.pdf Accessed Feb 17, 2010. 74. Kuemmerle-Deschner J.B., Tzaribachev N., Hansmann S. et al. Longlasting response to ACZ885 (a new human IgG1 anti-IL-1β monoclonal antibody) in patients with Muckle-Wells Syndrome (MWS) [abstract]. Clin Exp Rheumatol 2008;26:180. 75. Dhimolea E. Canakinumab. MAbs 2010;2:3-13.</p><p>Dinarello C.A. Interleukin-1β and the Autoinflammatory Diseases. New Engl J Med 2009;360:2467-70</p><p>Simon A., van der Meer J.W. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 2007;292:R86-R98.</p><p>Chae J.J., Wood G., Richard K. et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 2008;112:1794-803.</p><p>Chae J.J., Wood G., Masters S.L. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006;103:9982-7. 80. Roldan R., Ruiz A.M., Miranda M.D., Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008;75:504-5.</p><p>Lobito A.A., Kimberley F.C., Muppidi J.R. et al. Abnormal disulfidelinked oligomerization results in eR retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006;108:1320-7.</p><p>Todd I., Radford P.M., Daffa N. et al. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptorassociated periodic syndrome is altered antigenically and is retained within patientsleukocytes. Arthr Rheum 2007;56:2765-73.</p><p>Gattorno M., Pelagatti M.A., Meini A. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptorassociated periodic syndrome. Arthr Rheum 2008;58:1516-20.</p><p>Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009;27:621-68.</p><p>Mandey S.H., Kuijk L.M., Frenkel J., Waterham H.R. A role for geranylgeranylation in interleukin-1β secretion. Arthr Rheum 2006;54:3690-5.</p><p>Kuijk L.M., Beekman J.M., Koster J. et al. HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008;112:3563-73.</p><p>Cailliez M., Garaix F., Rousset-Rouviere C. et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 2006;29:763.</p><p>Hoffman H.M., Mueller J.L., Broide D.H. et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5.</p><p>Agostini L., Martinon F., Burns K. et al. NLRP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25</p><p>Hoffman H. M., Rosengren S., Boyle D.L. et al. Prevention of cold associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85.</p><p>Hoffman H.M., Throne M.L., Amar N.J. et al. Efficacy and safety of rilonacept (interleukin1 Trap) in patients with cryopyrinassociated periodic syndromes: results from two sequential placebo-controlled studies. Arthr Rheum 2008;58:2443-52</p><p>Lachmann H. J., Kone-Paut I., Kuemmerle-Deschner J.B. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. New Engl J Med 2009;360:2416-25.</p><p>Savic S., McDermott M.F. Canakinumab for the cryopyrin-associated periodic syndromes. Nat Rev Rheum 2009;5:529-30.</p><p>Lachmann H.J., Lowe P., Felix S.D. et al. In vivo regulation of interleukin-1 beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206:1029-36.</p><p>Kuemmerle-Deschner J.B., Lachmann H.J., Hachulla E. et al. Efficacy and safety of canakinumab (Ilaris) in a large cohort of patients across different severity phenotypes of cryopyrin associated periodic syndrome (CAPS) [abstract]. Arthr Rheum 2009;60:(Suppl. 10):1235.</p><p>Goldbach-Mansky R., Shroff S.D., Wilson M. et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthr Rheum 2008;58:2432-42.</p><p>De Koning H.D., Bodar E.J., van der Meer J.W., Simon A. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthr Rheum 2007;37:137-48.</p><p>Pascual V., Allantaz F., Arce E. et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.</p><p>Gattorno M., Piccini A., Lasiglie D. et al. The pattern of response to anti-interleukin1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthr Rheum 2008;58:1505-15.</p><p>Kelly A., Ramanan A.V. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008;4:615-20.</p><p>Lequerre T., Quartier P., Rosellini D. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemiconset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8.</p><p>Fitzgerald A.A., Leclercq S.A., Yan A. et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthr Rheum 2005;52:1794-803.</p><p>Ruperto N. A phase II trial with Canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis (SJIA) [abstract -OP-0298]. Ann Rheum Dis 2009;68(Suppl. 3):170.</p><p>Ginsberg M.H., Kozin F., Chow D. et al. Adsorption of polymorphonuclear leukocyte lysosomal enzymes to monosodium urate crystals. Arthr Rheum 1977;20:1538-42.</p><p>Guerne P.A., Terkeltaub R., Zuraw B., Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthr Rheum 1989;32:1443-52.</p><p>Pouliot M., James M.J., McColl S.R. et al. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998;91:1769-76</p><p>Bouchard L., de Medicis R., Lussier A. et al. Inflammatory microcrystals alter the functional phenotype of human osteoblastlike cells in vitro: synergism with IL-1 to overexpress cyclooxygenase-2. J Immunol 2002;168:5310-7.</p><p>Di Giovine F.S., Malawista S.E., Nuki G., Duff G.W. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987;138:3213-8.</p><p>Di Giovine F.S., Malawista S.E., Thornton E., Duff G.W. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. J Clin Invest 1991;87:1375-81.</p><p>Matsukawa A., Yoshimura T., Maeda T. et al. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin1 beta, interleukin-8, and interleukin1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998;78:559-69.</p><p>Seegmiller J.E., Howell R.R., Malawista S.E. The inflammatory reaction to sodium urate. JAMA 1962;180:469-75.</p><p>McCarty D.J. The inflammatory reaction to microcrystalline sodium urate. Arthr Rheum 1965;8:726-35.</p><p>Е.Л., Насонова В.А., Барскова В.Г. Механизмы развития подагрического воспаления. Тер арх 2006;6:77-84.</p><p>Malawista S.E., Duff G.W., Atkins E. et al. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthr Rheum 1985;28:1039-46.</p><p>Martinon F., Petrilli V., Mayor A. et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.</p><p>Pope R.M., Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthr Rheum 2007;56:3183-8.</p><p>Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004;117:561-74.</p><p>Cronstein R.N., Terkeltaub R. The inflammatory process of gout and its treatment. Arthr Res Ther 2006;8(Suppl. 1):S3. 119. Edwards N.L. Treatment-failure gout: A moving target. Arthr Rheum 2008;58:2587-90</p><p>So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthr Res Ther 2007;9:R28.</p><p>Announ N., Palmer G., Guerne P.A., Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in endstage renal failure. Joint Bone Spine 2009;76:424-6.</p><p>Terkeltaub R., Sundy J.S., Schumacher H.R. et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-7.</p><p>So A., De Meulemeester M., Pikhlak A. et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, doseranging study. Arthr Rheum 2010;62:3064-76</p><p>Schlesinger N. Efficacy of canakinumab (ACZ885) in the prevention of flares in gout patients initiating allopurinol therapy. EULAR 2010, Abstract OP0198.</p><p>Church L.D., McDermott M.F. Canakinumab, a fully human mAb against IL-1β for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-9.</p><p>Picco P., Brisca G., Traverso F. et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): an unrecognized autoinflammatory disease- Arthr Rheum 2009;60:264-8.</p><p>Larsen C.M., Faulenbach M., Vaag A. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl J Med 2007;356:1517-26</p><p>Lust J.A. Lacy M.Q., Zeldenrust S.R. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1βinduced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009;84:114-22.</p><p>Merhi-Soussi F., Kwak B.R., Magne D. et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein e-knockout mice. Cardiovasc Res 2005;66:583-93</p></div><br />
Рецензия
Для цитирования:
Ильина А.Е., Станислав М.Л., Денисов Л.Н., Насонов Е.Л. ИНТЕРЛЕЙКИН 1 КАК МЕДИАТОР ВОСПАЛЕНИЯ И ТЕРАПЕВТИЧЕСКАЯ МИШЕНЬ. Научно-практическая ревматология. 2011;49(5):62-71. https://doi.org/10.14412/1995-4484-2011-1463
For citation:
Il'ina A.E., Stanislav M.L., Denisov L.N., Nasonov E.L. INTERLEIKIN 1 KAK MEDIATOR VOSPALENIYa I TERAPEVTIChESKAYa MIShEN''. Rheumatology Science and Practice. 2011;49(5):62-71. (In Russ.) https://doi.org/10.14412/1995-4484-2011-1463
Просмотров:
1593
Послать статью по эл. почте 